Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 73
Filter
4.
6.
J Drugs Dermatol ; 16(12): 1198-1206, 2017 12 01.
Article in English | MEDLINE | ID: mdl-29240855

ABSTRACT

Lawrence transfer factor (TF) is defined as dialyzable leukocyte extract (DLE) that can transfer antigen-specific cell-mediated immunity from a person testing positive for the antigen in a delayed type hypersensitivity skin test manner to a person negative for the same antigen. A recent article by Myles et al1 has identified a DLE isolated from an established CD8+ T cell line capable of transferring antigen-specific immunity. The DLE contains a portion of the beta chain of the T cell receptor and additional nucleotide and protein factors that are being subjected to further modern biochemical analysis. After months of study that included interviews of TF physician-scientists, we conclude that an antigen-specific TF exists for most, if not all, antigens. By working from a CD8+ T cell line with modern biochemical technology, it should be possible to identify and patent products capable of treating infectious diseases, antigen-responsive cancers, and autoimmune disorders.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Transfer Factor/immunology , Cell Line , Humans , Immunity, Cellular , Immunologic Memory
7.
Emerg Infect Dis ; 23(11): 1928, 2017 11.
Article in English | MEDLINE | ID: mdl-29048282

ABSTRACT

Autochthonous leprosy has been reported in New York City, where there are no wild armadillos. Recent autochthonous cases also have been reported in Georgia and Florida and blamed on armadillos, including cases with no known armadillo exposure. International migration needs to be considered as a cause of autochthonous leprosy.


Subject(s)
Disease Transmission, Infectious , Leprosy/transmission , Mycobacterium leprae/isolation & purification , Florida/epidemiology , Georgia/epidemiology , Humans , Leprosy/epidemiology , Leprosy/microbiology , New York City/epidemiology
10.
Neurodiagn J ; 57(2): 147-152, 2017.
Article in English | MEDLINE | ID: mdl-28622133

ABSTRACT

Synchronous video recording can be helpful in EEG recordings, especially in recognition of seizures and in rejection of artifacts. However, video recordings themselves are also subject to the risk of contamination by artifacts. We report a unique case in which a digital video artifact was identified, occurring during synchronous video-EEG recording, albeit independently of the EEG tracing itself. A synchronous digital video-EEG recording was performed on a 67-year-old male who presented in focal motor status epilepticus. During the initial review of the data, right-sided abnormalities on EEG apparently corresponded with (ipsilateral) right arm motor activity on video, suggesting a nonsensical anatomical localization. However, review of the patient's chart and discussion with the EEG technologist led to the recognition that the video data recorded a mirror image of the true findings of left arm motor activity. Review of the software settings led to the discovery that the video recording was inverted along the vertical axis, leading to mirror image video artifact. Recognition of this video artifact allowed for accurate interpretation of the study-that right hemispheric EEG abnormalities correlated appropriately with (contralateral) left arm twitching. Effective communication between the EEG reading physician, the treating team, and the EEG technologist is critical for recognition of such artifacts, for proper EEG interpretation, and for appropriate patient management. Mirror image video artifact affirms that bedside evaluation, astute technologists, and attentive EEG reading physicians remain important, even in the presence of video recording.


Subject(s)
Artifacts , Electroencephalography/methods , Image Interpretation, Computer-Assisted , Video Recording , Aged , Anticonvulsants/therapeutic use , Humans , Image Interpretation, Computer-Assisted/methods , Image Interpretation, Computer-Assisted/standards , Magnetic Resonance Imaging , Male , Seizures/diagnosis , Seizures/drug therapy , Seizures/physiopathology , Video Recording/methods , Video Recording/standards
12.
J Leukoc Biol ; 100(1): 47-54, 2016 07.
Article in English | MEDLINE | ID: mdl-27106673

ABSTRACT

Leprosy is a disease caused by Mycobacterium leprae that presents on a spectrum of both clinical manifestations and T cell response. On one end of this spectrum, tuberculoid leprosy is a well-controlled disease, characterized by a cell-mediated immunity and immunosurveillance. On the opposite end of the spectrum, lepromatous leprosy is characterized by M. leprae proliferation and T cell anergy. Similar to progressive tumor cells, M. leprae escapes immunosurveillance in more severe forms of leprosy. The mechanisms by which M. leprae is able to evade the host immune response involve many, including the alterations of lipid droplets, microRNA, and Schwann cells, and involve the regulation of immune regulators, such as the negative checkpoint regulators CTLA-4, programmed death 1, and V-domain Ig suppressor of T cell activation-important targets in today's cancer immunotherapies. The means by which tumor cells become able to escape immunosurveillance through negative checkpoint regulators are evidenced by the successes of treatments, such as nivolumab and ipilimumab. Many parallels can be drawn between the immune responses seen in leprosy and cancer. Therefore, the understanding of how M. leprae encourages immune escape during proliferative disease states has potential to add to our understanding of cancer immunotherapy.


Subject(s)
Immunity, Cellular/immunology , Leprosy/immunology , Models, Biological , Neoplasms/immunology , T-Lymphocytes/immunology , Animals , Humans , Lymphocyte Activation
13.
J Investig Dermatol Symp Proc ; 17(2): 16-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26551938

ABSTRACT

Diphencyprone (DPCP) is a potent topical sensitizing agent that has been used since the late 1970s by physicians for the treatment of alopecia areata (AA), viral warts (human papillomavirus) and cutaneous metastases of melanoma. Although to date the compound is not approved as a drug by the FDA or EMA, physicians have continued to use DPCP because of its proven effects in these dermatological conditions. The use of the drug has been highly variable because of differences in compounding, and as a result, the literature reports vary widely in the concentrations used for sensitization and challenge treatment with DPCP. The efficacy of DPCP has generally been ascribed to immunological reactions by the host. Inducing inflammation with a contact sensitizer is counterintuitive to treating AA, an autoimmune disorder. We have hypothesized that the body's attempt to downregulate the inflammation caused by the contact sensitizer may also ameliorate AA. Studies using microarray and miRNA profiling may provide information about how DPCP induces inflammation in human skin at different times. Gene targets and microRNAs identified through these data may be modulated by an RNA interference approach to enhance DPCP efficacy and response rates. In addition, this approach may result in the discovery and development of drugs that are more potent and selective for the treatment of AA.


Subject(s)
Alopecia Areata/drug therapy , Cyclopropanes/pharmacology , Dermatologic Agents/pharmacology , Gene Expression Regulation/drug effects , Inflammation/genetics , RNA Interference , Alopecia Areata/genetics , Alopecia Areata/immunology , Autoimmune Diseases/drug therapy , Combined Modality Therapy , Cyclopropanes/therapeutic use , Dermatologic Agents/therapeutic use , Down-Regulation , Humans , Inflammation/drug therapy , Up-Regulation
15.
Clin Infect Dis ; 61(9): 1439-40, 2015 Nov 01.
Article in English | MEDLINE | ID: mdl-26209684

ABSTRACT

Five of 10 paucibacillary leprosy patients were Quantiferon Gold (Q-G) positive with negative chest X-rays. Forty multibacillary leprosy patients were negative. Reports have shown 100% cross-reactivity of ESAT6 and CFP10 between Mycobacterium leprae and Mycobacterium tuberculosis. The Q-G test cannot detect latent tuberculosis in patients with leprosy.


Subject(s)
Diagnostic Errors , Interferon-gamma Release Tests/methods , Latent Tuberculosis/diagnosis , Leprosy/complications , Antigens, Bacterial/immunology , Cross Reactions , Humans , Mycobacterium leprae/immunology , Mycobacterium tuberculosis/immunology
19.
J Drugs Dermatol ; 13(10): 1194-6, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25607553

ABSTRACT

Prior studies have identified local heat therapy as a treatment for recalcitrant warts. We have employed a thermal pad that raises local temperature to 42-43ºC for at least 2 hours in a proof of concept study of three patients with recalcitrant warts. The recalcitrant warts cleared in all three patients beginning in the fourth and fifth weeks after daily treatment with the pads. There were no adverse events. We conclude that the timing of clearance following use of these thermal pads is likely via direct viral killing and immunologic mechanisms. Further controlled trials are underway.


Subject(s)
Hot Temperature , Occlusive Dressings , Warts/therapy , Adult , Female , Humans , Male , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...